HHS and the DEA have moved to restrict higher-concentration 7-OH and MGPI products — with changes that could take effect as early as Friday, Nov. 13, 2026 — while leaving traditional botanical kratom outside the crackdown. For clinicians, the shift matters because 7-OH is being sold in gas stations and smoke shops, is reported by some patients as opioid-like, and is increasingly tied to dependence, withdrawal and poison-center calls.

The Move

• Federal officials narrowed an earlier crackdown after HHS issued an Oct. 9 recommendation and the DEA revised course.

• The likely restriction now targets higher-concentration 7-hydroxymitragynine (7-OH) and/or mitragynine pseudoindoxyl (MGPI) products, not traditional kratom leaf products.

• Earlier, the DEA had placed three semi-synthetic opioids — MGM-15, MGM-16 and MGPI — alongside the most restricted Controlled Substances Act drugs, prompting backlash and a lawsuit from the American Kratom Association.

• Products at issue are widely sold as tablets, gummies, tonics and chocolates in smoke shops, gas stations, liquor stores and online.

Why it Matters for Care

• Patients may not recognize 7-OH as an opioid-like exposure, especially when products are marketed simply as “kratom.”

• Researchers and clinicians interviewed described dependence and withdrawal that can resemble — and in some cases be perceived as worse than — prior opioid withdrawal.

• Bedside implication: ask specifically about kratom extracts, 7-OH tablets/gummies/shots, and purchase sites like smoke shops or gas stations when evaluating pain, sedation, GI symptoms, anxiety, insomnia or unexplained withdrawal.

• Poison-center data cited in the story found kratom-related calls rose about 1,200% from 2015 to 2025; the report included 233 deaths, with 79% involving multiple substances.

• Co-use appears clinically important: the most severe outcomes were linked to concurrent opioids, stimulants and benzodiazepines.

Between the Lines

• Washington is trying to split the difference: avoid a politically explosive ban on traditional kratom while tightening access to more potent, concentrated derivatives.

• The pressure is coming from both sides — patients who say these products help with pain or opioid recovery, and addiction clinicians seeing a growing number of 7-OH-related cases.

• The evidence base remains muddy because surveillance and prevalence estimates often lump whole-leaf kratom together with concentrated 7-OH products.

• That distinction matters: NIDA researchers say early signals suggest 7-OH may carry higher addiction risk than whole-leaf kratom.

What to Watch

• Whether the federal restriction takes effect on the expected Nov. 13 timeline.

• Possible court action or further challenges from kratom-industry and advocacy groups.

• How the DEA defines “higher concentrations” in practice, and whether enforcement reaches products with trace amounts.

• Whether states move faster than the federal government to restrict or relabel 7-OH products.

• Whether clinicians begin seeing substitution effects — either return to other opioids, more whole-leaf kratom use, or increased demand for addiction treatment and withdrawal management.

Source: NPR Health